457 related articles for article (PubMed ID: 12872509)
1. [All proton pump inhibitors are equally efficacious in standard dosages].
Hellström PM; Vitols S
Lakartidningen; 2003 Jun; 100(25):2212-6. PubMed ID: 12872509
[TBL] [Abstract][Full Text] [Related]
2. Esomeprazole 40 mg provides more effective intragastric acid control than lansoprazole 30 mg, omeprazole 20 mg, pantoprazole 40 mg and rabeprazole 20 mg in patients with gastro-oesophageal reflux symptoms.
Röhss K; Lind T; Wilder-Smith C
Eur J Clin Pharmacol; 2004 Oct; 60(8):531-9. PubMed ID: 15349707
[TBL] [Abstract][Full Text] [Related]
3. Relative efficacies of gastric proton-pump inhibitors on a milligram basis: desired and undesired SH reactions. Impact of chirality.
Kromer W
Scand J Gastroenterol Suppl; 2001; (234):3-9. PubMed ID: 11768559
[TBL] [Abstract][Full Text] [Related]
4. Healing and relapse rates in gastroesophageal reflux disease treated with the newer proton-pump inhibitors lansoprazole, rabeprazole, and pantoprazole compared with omeprazole, ranitidine, and placebo: evidence from randomized clinical trials.
Caro JJ; Salas M; Ward A
Clin Ther; 2001 Jul; 23(7):998-1017. PubMed ID: 11519776
[TBL] [Abstract][Full Text] [Related]
5. Gastric acid control with esomeprazole, lansoprazole, omeprazole, pantoprazole, and rabeprazole: a five-way crossover study.
Miner P; Katz PO; Chen Y; Sostek M
Am J Gastroenterol; 2003 Dec; 98(12):2616-20. PubMed ID: 14687806
[TBL] [Abstract][Full Text] [Related]
6. Relative efficacies of gastric proton pump inhibitors: their clinical and pharmacological basis.
Kromer W; Horbach S; Lühmann R
Pharmacology; 1999 Aug; 59(2):57-77. PubMed ID: 10450061
[TBL] [Abstract][Full Text] [Related]
7. Comparison of inhibitory effects of the proton pump-inhibiting drugs omeprazole, esomeprazole, lansoprazole, pantoprazole, and rabeprazole on human cytochrome P450 activities.
Li XQ; Andersson TB; Ahlström M; Weidolf L
Drug Metab Dispos; 2004 Aug; 32(8):821-7. PubMed ID: 15258107
[TBL] [Abstract][Full Text] [Related]
8. What is potent acid inhibition, and how can it be achieved?
Calvet X; Gomollón F
Drugs; 2005; 65 Suppl 1():13-23. PubMed ID: 16335854
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of omeprazole, lansoprazole, pantoprazole, and rabeprazole in the treatment of acid-related diseases.
Welage LS; Berardi RR
J Am Pharm Assoc (Wash); 2000; 40(1):52-62; quiz 121-3. PubMed ID: 10665250
[TBL] [Abstract][Full Text] [Related]
10. [New-generation proton pump inhibitors: progress in the treatment of peptic acid diseases?].
de Korwin JD; Ducrotté P; Vallot T
Presse Med; 2004 Jun; 33(11):746-54. PubMed ID: 15257232
[TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness comparison of current proton-pump inhibitors to treat gastro-oesophageal reflux disease in the UK.
Remák E; Brown RE; Yuen C; Robinson A
Curr Med Res Opin; 2005 Oct; 21(10):1505-17. PubMed ID: 16238890
[TBL] [Abstract][Full Text] [Related]
12. New-generation proton pump inhibitors: overcoming the limitations of early-generation agents.
Robinson M
Eur J Gastroenterol Hepatol; 2001 May; 13 Suppl 1():S43-7. PubMed ID: 11430508
[TBL] [Abstract][Full Text] [Related]
13. Are the orally administered proton pump inhibitors equivalent? A comparison of lansoprazole, omeprazole, pantoprazole, and rabeprazole.
Thomson AB
Curr Gastroenterol Rep; 2000 Dec; 2(6):482-93. PubMed ID: 11079051
[TBL] [Abstract][Full Text] [Related]
14. An overview of proton pump inhibitors.
Der G
Gastroenterol Nurs; 2003; 26(5):182-90. PubMed ID: 14603076
[TBL] [Abstract][Full Text] [Related]
15. A comparison of omeprazole, lansoprazole and pantoprazole in the maintenance treatment of severe reflux oesophagitis.
Jaspersen D; Diehl KL; Schoeppner H; Geyer P; Martens E
Aliment Pharmacol Ther; 1998 Jan; 12(1):49-52. PubMed ID: 9692700
[TBL] [Abstract][Full Text] [Related]
16. Cost-minimization analysis of treatment of gastroesophageal reflux disease. Implications of varying holding time on conclusions.
Kivioja A; Linnosmaa I; Vehviläinen A; Vohlonen I
Eur J Pharm Sci; 2004 Feb; 21(2-3):171-8. PubMed ID: 14757488
[TBL] [Abstract][Full Text] [Related]
17. [Dosaging of proton pumps inhibitors].
Brørs O
Tidsskr Nor Laegeforen; 2006 Sep; 126(18):2397-9. PubMed ID: 16998554
[No Abstract] [Full Text] [Related]
18. A double-blind, randomized comparison of omeprazole Multiple Unit Pellet System (MUPS) 20 mg, lansoprazole 30 mg and pantoprazole 40 mg in symptomatic reflux oesophagitis followed by 3 months of omeprazole MUPS maintenance treatment: a Dutch multicentre trial.
Mulder CJ; Westerveld BD; Smit JM; Oudkerk Pool M; Otten MH; Tan TG; van Milligen de Wit AW; de Groot GH;
Eur J Gastroenterol Hepatol; 2002 Jun; 14(6):649-56. PubMed ID: 12072599
[TBL] [Abstract][Full Text] [Related]
19. Rabeprazole: a review of its use in acid-related gastrointestinal disorders.
Langtry HD; Markham A
Drugs; 1999 Oct; 58(4):725-42. PubMed ID: 10551440
[TBL] [Abstract][Full Text] [Related]
20. Twice-daily dosing of esomeprazole effectively inhibits acid secretion in CYP2C19 rapid metabolisers compared with twice-daily omeprazole, rabeprazole or lansoprazole.
Sahara S; Sugimoto M; Uotani T; Ichikawa H; Yamade M; Iwaizumi M; Yamada T; Osawa S; Sugimoto K; Umemura K; Miyajima H; Furuta T
Aliment Pharmacol Ther; 2013 Nov; 38(9):1129-37. PubMed ID: 24099474
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
